“In-situ hybridization (ISH) is a powerful technique used for focusing on specific nucleic acid targets within fixed tissues and cells, to obtain temporal and spatial information about gene expression. The in-situ hybridization technique is divided into two types, namely DNA and RNA. This is because, normally ISH requires isolation of DNA or RNA which is done by separating it on a gel, blotting it onto nitrocellulose, and probing it with a complementary sequence.
The global in-situ hybridization market was valued at $554.4 million 2014, and is estimated to reach $681.0 million by 2019, at a CAGR of 4.2% from 2014 to 2019.
The global in-situ hybridization market is primarily driven by the increasing prevalence of cancer disease, growing usage of personalized medicines for its treatment, and rising number of initiatives undertaken by the government, such as create awareness about cancer and providing funding to support related researches.
Some of the companies profiled in this report are Abbott (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Affymetrix, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), and Agilent Technologies, Inc. (U.S.).
“
